Received for publication May 27, 2008.
Revised August 4, 2008.
Accepted for publication August 5, 2008.

Dynamic Effect of Bortezomib on NF-B Activity and Gene Expression in Tumor Cells

Abstract

NF-B influences the initiation, progression, and maintenance of diverse cancer types. Despite current therapeutic efforts to block hyperactive NF-B in cancer cells, the in vivo effects of a drug upon this complex pathway are unclear. We monitored NF-B activity and a fast-expressing reporter level simultaneously in head and neck squamous carcinoma cells by quantitative live microscopy. The real time single cell assay revealed the TNF- induced oscillation of NF-B was echoed by equally dynamic reporter expression rate. Bortezomib is a proteasome inhibitor whose anti-cancer action is partly mediated through inhibition of NF-B. When administered to pre-activated cells, the drug gave rise to distinct inhibition dynamics, with discrete pulses of reporter induction remaining for hours. These findings suggest that, contrary to a simplistic presumption for a pathway 'blockade', the network dynamics and the intracellular pharmacokinetics of the inhibitor must be critically evaluated in developing strategies for optimal intervention of oncogenic pathways.

Key words: Tumor necrosis factor, NFkappaB, Thermodynamic and kinetic processes and modeling, Optical spectroscopy (fluorescence, DC, etc.), Regulation of gene expression, Oncogenes, Pharmacokinetics, metabolism and activation

This article has been cited by other articles:

				P. Arun, M. S. Brown, R. Ehsanian, Z. Chen, and C. Van Waes Nuclear NF-{kappa}B p65 Phosphorylation at Serine 276 by Protein Kinase A Contributes to the Malignant Phenotype of Head and Neck Cancer Clin. Cancer Res., October 1, 2009; 15(19): 5974 - 5984. [Abstract] [Full Text] [PDF]